{
    "id": "5c65484ee842deac6700001f",
    "question": "Can mogamulizumab be used for the treatment of cutaneous T-cell lymphoma?",
    "options": {
        "A": "yes",
        "B": "no"
    },
    "answer": "A",
    "predict": "{\"step_by_step_thinking\": \"Mogamulizumab is a humanized monoclonal antibody that targets the \\u00b14T cell (CD25) subpopulation of T cells, which are often found in cutaneous T-cell lymphoma (CTCL). Research has shown that mogamulizumab can effectively reduce the expression of CD25 on these T cells, leading to a decrease in the proliferation and survival of these cells. As a result, mogamulizumab has been investigated as a potential therapeutic option for the treatment of CTCL. In clinical trials, mogamulizumab has demonstrated efficacy in reducing skin lesions and improving symptoms in patients with CTCL. Therefore, based on the available evidence, mogamulizumab can be used for the treatment of cutaneous T-cell lymphoma.\", \"answer_choice\": \"A\"}",
    "snippets": [],
    "scores": [],
    "execution_time": 29.834869623184204
}